Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsSunpharmaceuticalindustries

    At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

    Jump to

    • Sun Pharma Q1 PAT may rise 42% at Rs 959 cr: Motilal Oswal

      Motilal Oswal expects Sun Pharmaceutical Industries to report a 1 percent growth quarter-on-quarter (rise of 42.2 percent year-on-year) in net profit at Rs 959 crore.

    • Sun Pharma Q1 net profit seen up 30% to Rs 1,035cr

      Sun Pharma's revenue is expected to rise 23 percent year-on-year to Rs 3,287 crore, driven by over 20 percent growth in US sales. Domestic formulations sales are, however, likely to be lower due to the impact of the new drug pricing policy.

    • Muted earnings growth likely in Q1FY14: Nirmal Bang

      Nirmal Bang research expects the companies in their coverage universe to post a 4.4% YoY revenue growth, a 1% decline in EBITDA and a 7.2% fall in net profit. The performance reflects demand slowdown in the economy amid a depreciating Indian rupee.

    • Kotak downgrades Sun Pharma, Bharat Forge

      The firm believes that Sun Pharma is likely to touch a target price of Rs 825 per share.

    • Jefferies raises Sun Pharma target price after a strong Q4

      Jefferies maintained a "buy" and raised its target price on Sun Pharma after its fourth quarter results beat street expectations. UBS, meanwhile, has a "neutral" rating.

    • Credit Suisse ups target of Sun Pharma, Coal India, Colgate

      Credit Suisse has raised target price of Coal India, Sun Pharmaceutical Industries and Colgate Palmolive (India). The broking firm has also revised EPS estimates of these companies as well.

    • What to expect from Sun Pharma in Q4

      Sun Pharmaceutical Indusries' fourth quarter revenues may rise by 26 percent year-on-year to Rs 2,946 crore during the March quarter.

    • IIFL gung-ho on pharma, expects Sun to beat Q4 estimates

      Bino Pathiparampil of IIFL, says that stock like Sun Pharma has been beating estimates for last eight quarters and the same performance is likely to continue in this quarter. Ranbaxy‘s business has been worsening over the last 2-3 quarters and one can‘t expect major improvement to happen in the base business.

    • Pharma cos likely to post 21% EBITDA growth in Q4: MOST

      Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).

    • Find out: FMCG, pharma, Oil& Gas who will lead Q4 earnings?

      The fourth quarter earnings will begin from Friday. In an interview to CNBC-TV18, Varatharajan Sivasankaran of ICICI Securities outlined his expectations from stocks across various sectors.

    • Sun Pharma Q3 net seen up 25% to Rs 838cr on Taro, Lipodox

      Healthcare firm Sun Pharmaceutical is set to announce its third quarter results on Friday. Analysts on an average were expecting profit after tax to grow by 25 percent year-on-year to Rs 838 crore in the quarter, helped by Taro numbers and Lipodox generic.

    • Good performance likely from pharma in Q3: Nirmal Bang

      Nirmal Bang has come out with its earnings estimates for pharmaceutical sector for the quarter ended December 2012. The research firm feels margins of pharma companies may witness YoY expansion owing to rupee depreciation (6 percent YoY).

    • See pharma sector's Q3 topline to grow 22%: Motilal Oswal

      Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.

    • See pharma sector's Q3 adj PAT to grow 26% YoY: P Lilladher

      Prabhudas Lilladher has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects top-line growth of 24 percent YoY for its coverage universe (excluding one-offs), with EBITDA growth at a robust 24 percent YoY.

    • See pharma sector's margins to dip 314 bps in 3QFY13: Angel

      Angel Broking has come out with earning expectations for pharmaceutical sector for the October-December quarter of 2012. The research firm expects the Indian pharma sector to post lackluster numbers for 3QFY2013 on the sales front.

    • Q2 earnings: 9 stocks that beat estimates; 10 that didn't

      With the September quarter earnings season just concluded, analysts are now taking stock of the numbers, and the hits and misses.

    • Sun Pharm Q2 revenues seen up 46% to Rs 2,764 cr

      Healthcare firm Sun Pharmaceutical Industries' revenues are seen going up by 46 percent YoY (of which 30.8% contribution by Taro) to Rs 2,764 crore in September quarter.

    • Sun Pharma Q2 PAT seen up 40% YoY to Rs 835 cr

      Healthcare firm Sun Pharmaceutical Industries is set to announce its second quarter earnings on Thursday. Analysts on an average expect the numbers to be strong due to consolidation of TARO.

    • Sun Pharma Q1 net profit seen up 31% to Rs 654 cr

      Sun Pharmaceutical Industries, one of the India's largest drug manufacturers by market value, is set to announce its results for the quarter ended June 2012 on Friday. Analysts on an average expect the consolidated net profit to grow by 30.58% year-on-year to Rs 654.22 crore.

    • Earnings watch: Which pharma co is in pink of its health?

      In an interview to CNBC-TV18 Bino Pathiparampil of IIFL shared his expectation from various pharmaceutical companies ahead for their earnings.

    • Adj PAT of healthcare sector likely to grow 11% YoY: MOSt

      Motilal Oswal expects topline growth of 22% YoY for their Healthcare universe (excluding one-offs), with robust EBITDA growth of 35% YoY. Adjusted PAT is likely to grow 11% YoY, says Motilal Oswal.

    • Margins may be hit on one-off items in EBITDA: Sun Pharma

      Uday Baldota, VP- investor relations, Sun Pharma tells CNBC-TV18 that apart from the drug Taro‘s stellar contribution, other business segments also performed well

    • Sun Pharma Q4 net sales up 60% at Rs 2330 cr

      Drug maker Sun Pharma posted a spectacular 85% jump in March quarter net profit at Rs 820 crore, driven by strong sales of its Israeli unit Taro.

    • Sun Pharma expects 18-20% FY13 sales growth

      Sun Pharmaceutical expects 18-20% sales growth in the current fiscal year that started in April, Managing Director Dilip Shanghvi said in an earnings conference call on Wednesday.

    • Sun Pharma Q3 PAT seen up 65% at Rs 576 cr

      Sun Pharmaceutical Industries, country's largest drugmaker by market cap, is set to announce its results for the quarter ended December FY12 on Monday, February 13. The company's profit after tax is likely to shoot up 65% to Rs 576 crore from Rs 350 crore year-on-year.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347